Neurology and Neurosurgery - Global Neurology Academy

209-224 of 481

Next Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
Next Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
NeuroFrontiers
Next Steps in Gene Therapy Research for Duchenne Muscular Dystrophy
Craig M. McDonald, MD
- Craig M. McDonald, MD
Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
NeuroFrontiers
Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels
Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination
Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination
NeuroFrontiers
Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination
Christian Cordano, MD, PhD
- Christian Cordano, MD, PhD
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
NeuroFrontiers
Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays
Nancy Kuntz, MD
- Nancy Kuntz, MD
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
NeuroFrontiers
Duchenne Muscular Dystrophy Management: Analyzing Current Approaches
Nancy Kuntz, MD
- Nancy Kuntz, MD
Advances in MS Management: Current and Future Directions
Advances in MS Management: Current and Future Directions
NeuroFrontiers
Advances in MS Management: Current and Future Directions
From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia
From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia
NeuroFrontiers
From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia
Ashley Baker, MSN, PMHNP; Steven Paul, MD
- Ashley Baker, MSN, PMHNP
- Steven Paul, MD
Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events
Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events
NeuroFrontiers
Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events
Amber Salter, PhD
- Amber Salter, PhD
Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response
Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response
NeuroFrontiers
Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response
Pavan Barghava, MD
- Pavan Barghava, MD
Exploring Metabolomics in Multiple Sclerosis
Exploring Metabolomics in Multiple Sclerosis
NeuroFrontiers
Exploring Metabolomics in Multiple Sclerosis
Pavan Barghava, MD
- Pavan Barghava, MD
MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse
MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse
NeuroFrontiers
MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse
Michael Kornberg, MD, PhD
- Michael Kornberg, MD, PhD
Managing Multiple Sclerosis: The Impact of Dietary Modifications
Managing Multiple Sclerosis: The Impact of Dietary Modifications
On the Frontlines of Multiple Sclerosis
Managing Multiple Sclerosis: The Impact of Dietary Modifications
Charles Turck, PharmD, BCPS, BCCCP; Anna A. Shah, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Anna A. Shah, MD
Strategies and Considerations for Managing MS in Pregnant Women
Strategies and Considerations for Managing MS in Pregnant Women
On the Frontlines of Multiple Sclerosis
Strategies and Considerations for Managing MS in Pregnant Women
Charles Turck, PharmD, BCPS, BCCCP; Anna A. Shah, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Anna A. Shah, MD
Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health
Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health
NeuroFrontiers
Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health
Christopher Lock, MD
- Christopher Lock, MD
Emerging Technologies in MS: Neuromodulation and Myelin Regeneration
Emerging Technologies in MS: Neuromodulation and Myelin Regeneration
NeuroFrontiers
Emerging Technologies in MS: Neuromodulation and Myelin Regeneration
Cristin Welle, PhD
- Cristin Welle, PhD
Understanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD
Understanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD
NeuroFrontiers
Understanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD
Dalia Rotstein, MD, MPH
- Dalia Rotstein, MD, MPH

14/11